Profil de fragilité excluant les régimes intensifs de Burkitt (CODOX-M/IVAC ou DA-EPOCH-R...
Vue déterministe de l'entité source de la LJAM. L'autorité clinique demeure avec les ID de la source cités et l'état d'approbation de l ́examinateur.
| ID | RF-BURKITT-FRAILTY-AGE |
|---|---|
| Type | Signal d’alerte |
| État | reviewed 2026-04-27 | pending_clinical_signoff |
| Maladies | DIS-BURKITT |
| Sources | SRC-ESMO-BURKITT-2024 SRC-NCCN-BCELL-2025 |
Origine du drapeau rouge
| Définition | Frailty profile precluding intensive Burkitt regimens (CODOX-M/IVAC or DA-EPOCH-R full-dose): ECOG ≥3, OR (age ≥65 with G8 ≤14), OR composite frailty (age ≥70 + Charlson ≥3). Triggers de-escalation to attenuated R-mini-CHOP-like regimen or palliative R-CHOP — Burkitt curability dramatically lower in frail elderly. |
|---|---|
| Direction clinique | désescalade |
| Catégorie | âge de fragilité |
Logique de déclenchement
{
"any_of": [
{
"comparator": ">=",
"finding": "ecog",
"threshold": 3
},
{
"all_of": [
{
"comparator": ">=",
"finding": "age",
"threshold": 65
},
{
"comparator": "<=",
"finding": "g8_score",
"threshold": 14
}
]
},
{
"all_of": [
{
"comparator": ">=",
"finding": "age",
"threshold": 70
},
{
"comparator": ">=",
"finding": "charlson_score",
"threshold": 3
}
]
}
],
"type": "composite_score"
}
Notes
Burkitt is curable but cure rates collapse from 80-90% (young fit) to 20-40% (>65 frail) on full-intensity regimens — toxicity-driven treatment-related mortality is the dominant driver. NCCN B-Cell recommends DA-EPOCH-R (preferred over CODOX-M/IVAC) for fit elderly and modified DA-EPOCH-R or R-CHOP-like for frail. TLS prophylaxis mandatory regardless of dose intensity (rasburicase preferred over allopurinol given high TLS risk in Burkitt).
Utilisé par
Algorithmes
ALGO-BURKITT-1L- ALGO-BURKITT-1LALGO-BURKITT-2L- ALGO-BURKITT-2L